BCC Research highlights that Morphocell Technologies completed a $50 million Series A and is expanding into Europe.
Public source
Publisher name
Public post
"Corporate AI investment reached $252.3 billion in 2024 — a 44.5% rise in private funding and a 13-fold increase since 2014. A significant and growing share of that capi…
Company
BCC Research
Your trusted custom research and data analysts.
- Industry
- Market Research
- Location
- Boston, US
- Company size
- 201–500 employees
About BCC Research
Your trusted custom research and data analysts. At BCC Research, our mission is to provide businesses with reputable data and market research reports to better understand their field and target audience. We are dedicated to helping companies access reliable information, accurate forecasts, and actionable insights, to become a leader in their industry. Our goal is to help businesses make smart decisions based on data-driven insights, giving a competitive edge in their industry. We do this by creating a comprehensive analysis of trending topics, forecasting, and industry intelligence. We are with you, every step of the way! Reach out today to learn more.
See moreLatest activity
Latest activity from BCC Research
11 signals
Capital & Finance
BCC Research highlights that Cellino Biotech secured $25 million from ARPA-H in 2024 for AI-guided biomanufacturing in personalized regenerative medicine.
Capital & Finance
BCC Research highlights that Aspect Biosystems raised $115 million in a Series B round in January 2025 to advance AI-powered bioprinted tissue therapies.
Research & Knowledge
BCC Research published its latest Pulse Report titled AI Impact on Functional Foods and Beverages examining technologies, investment trends, key players, and strategic implications shaping the market.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Capital Cell
Capital Cell highlights that Cell Guidance Systems, founded in Cambridge in 2010 with an annual revenue of €1M, is raising capital to accelerate its extracellular-vesicle platform, strengthen the PODS® IP portfolio, and expand commercial activity in the United States.
Capital & Finance
SaxoCell Cluster
SaxoCell Cluster is entering its third funding phase for the Cell and Gene Therapy industry.
Capital & Finance
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine reported seven approvals between the United States and the European Union for its near-term cell and gene therapy pipeline in 2026.
Capital & Finance
BioCrowd
BioCrowd is funding $90 million into three science and technology centers for 5 years.
Capital & Finance
Qkine